Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Leases (2019 - 2023)

Spyre Therapeutics (SYRE) has disclosed Current Leases for 5 consecutive years, with $4.3 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Current Leases rose 807.97% year-over-year to $4.3 million, compared with a TTM value of $4.3 million through Jun 2023, up 807.97%, and an annual FY2022 reading of $625000.0, up 43.35% over the prior year.
  • Current Leases was $4.3 million for Q2 2023 at Spyre Therapeutics, up from $608000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $4.3 million in Q2 2023 and bottomed at $228000.0 in Q2 2020.
  • Average Current Leases over 5 years is $635352.9, with a median of $412000.0 recorded in 2021.
  • The sharpest move saw Current Leases dropped 9.12% in 2020, then soared 807.97% in 2023.
  • Year by year, Current Leases stood at $351000.0 in 2019, then decreased by 9.12% to $319000.0 in 2020, then surged by 36.68% to $436000.0 in 2021, then soared by 43.35% to $625000.0 in 2022, then surged by 592.96% to $4.3 million in 2023.
  • Business Quant data shows Current Leases for SYRE at $4.3 million in Q2 2023, $608000.0 in Q1 2023, and $625000.0 in Q4 2022.